继2024年12月宣布出售美国、英国细胞业务后,2025年1月13日,药明康德公告表示,出售间接控股子公司药明合联7.17%的股份,获取超20亿元收益。 获20.16亿元投资收益 1月13日,药明康德公告称,公司通过间接控股子公司持有联营企业药明合联的股票。2024年11月8日及2025年1月10日,通过两次大宗交易,公司累计出售药明合联8600万股股票,约占药明合联当前总股本的7.17%;...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.